RT Journal Article
SR Electronic
T1 Long COVID In Adults at 12 Months After Mild-to-Moderate SARS-CoV-2 Infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.12.21255343
DO 10.1101/2021.04.12.21255343
A1 Paolo Boscolo-Rizzo
A1 Francesco Guida
A1 Jerry Polesel
A1 Alberto Vito Marcuzzo
A1 Vincenzo Capriotti
A1 Andrea D’Alessandro
A1 Enrico Zanelli
A1 Riccardo Marzolino
A1 Chiara Lazzarin
A1 Paolo Antonucci
A1 Erica Sacchet
A1 Margherita Tofanelli
A1 Daniele Borsetto
A1 Nicoletta Gardenal
A1 Martino Pengo
A1 Giancarlo Tirelli
YR 2021
UL http://medrxiv.org/content/early/2021/04/13/2021.04.12.21255343.abstract
AB Background In a proportion of patients recovered from the acute COVID-19 phase, a variable range of symptoms has been observed to persist for at least 6-months.Objectives The main aim of this study was to evaluate the prevalence of COVID-related symptoms 12-months after the onset of mild-to-moderate disease.Methods Prospective study based on structured questionnaires and additional outcomes.Results 304/354 patients completing the survey at baseline also completed the follow-up interview (85.9%; median [range] age, 47 [18-76] years; 185 [60.9%] women). Persistence of at least one symptom at 12-months follow-up was reported by 161 patients (53.0%). The most commonly reported symptom of long COVID was felt tired (n=83, 27.3%), followed by smell or taste impairment (n=67, 22.0%), shortness of breath (n=39, 12.8%) and muscle pain (n=28, 9.2%). Being females (OR=1.64; 95% CI: 1.00-2.70), aged between 40-54 (OR=1.92; 95% CI: 1.07-3.44), having a BMI ≥25 (OR=1.67; 95% CI: 1.00-2.78), and experiencing more symptoms during the acute phase of the disease (OR=8.71 for ≥8 symptoms; 95% CI: 2.73-27.76) were associated with long COVID. Persistence of symptoms showed a significant impact on quality of life (p<0.0001) and depression scale scores (p=0.0102).Conclusion More than half of patients with previous mild-to-moderate symptomatic COVID-19 complained the persistence of at least one symptom 12-months after the onset of the illness.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Friuli Venezia Giulia Region (CEUR-2020-Os- 156)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe authors confirm that the data supporting the findings of this study are available within the article